2018
Prospective plasma efavirenz concentration assessment in Chinese HIV‐infected adults enrolled in a large multicentre study
Guo F, Cheng X, Hsieh E, Du X, Fu Q, Peng W, Li Y, Song X, Routy J, Li T. Prospective plasma efavirenz concentration assessment in Chinese HIV‐infected adults enrolled in a large multicentre study. HIV Medicine 2018, 19: 440-451. PMID: 29761920, PMCID: PMC6538474, DOI: 10.1111/hiv.12607.Peer-Reviewed Original ResearchLower body weightEfavirenz concentrationsBody weightWeek 4Chinese HIVMedian efavirenz concentrationPlasma efavirenz concentrationsAntiretroviral therapy initiationProspective multicentre trialProportion of patientsLarge multicentre studyPlasma samplesMultivariable regression analysisHigh efavirenz concentrationsNon-Han ethnicityEfavirenz 600Therapy initiationMulticentre trialMulticentre studyDosage reductionOptimal dosingTherapeutic windowPatientsSubstantial proportionHIV
2006
Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV
Friedland G, Khoo S, Jack C, Lalloo U. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. Journal Of Antimicrobial Chemotherapy 2006, 58: 1299-1302. PMID: 17032686, DOI: 10.1093/jac/dkl399.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlkynesAnti-HIV AgentsAntibiotics, AntitubercularBenzoxazinesCD4 Lymphocyte CountChromatography, High Pressure LiquidCyclopropanesDidanosineDrug Therapy, CombinationFemaleHIV InfectionsHumansLamivudineLongitudinal StudiesMaleOxazinesRifampinTreatment OutcomeTuberculosis, PulmonaryViral LoadConceptsExcellent clinical outcomesEfavirenz concentrationsClinical outcomesAntiretroviral therapyEfavirenz levelsAfrican patientsNon-detectable viral loadSmear-positive pulmonary TBLong-term clinical outcomesAdministration of efavirenzCD4 cell increaseHIV clinical outcomesPlasma efavirenz concentrationsCells/mm3Half of patientsTB regimenPulmonary TBPharmacokinetic interactionsTB outcomesTherapy completionRifampicin administrationViral loadTherapeutic rangePatientsHIV
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply